Antipodean Pharmaceuticals Initiates Phase II Trial For Parkinson’s Disease
MitoQ, based on a novel technology, targets lipophilic cations that transport and concentrate antioxidants into the mitochondria where they accumulate up to 1000 fold. Patients who meet the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.